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The effect of anastrozole on peripheral and tumour aromatase activity and oestrogen levels in postmenopausal patients with
oestrogen receptor-rich breast tumours was investigated. Twenty-six patients were randomly allocated to treatment with
anastrozole 1 mg (n=13) or 10 mg (n=13), once daily. Before and after 12 weeks’ treatment, patients were infused with
3H-D4
androstenedione (20 MBq) and
14C-oestrone (E1) (1 MBq) for 18 h. Oestrogens were puriﬁed from excised tumours and
plasma samples taken after each infusion. Peripheral and tumour aromatase activity and tumour E1 uptake were calculated from
levels of
3H and
14C in puriﬁed E1 fractions from tumour and plasma. Endogenous tumour oestrogens were measured by
radioimmunoassay. Twenty-three patients were available for analysis (1 mg group, n=12; 10 mg group, n=11). Following
treatment, anastrozole (1 and 10 mg) markedly inhibited peripheral aromatase in all patients (the difference between pre- and
on-treatment values being highly signiﬁcant P50.0001). In situ aromatase activity was also profoundly decreased by anastrozole
treatment in 16 of 19 tumours (the difference with treatment also being highly signiﬁcant P=0.0009). Most tumours were able
to concentrate E1 beyond levels in the circulation; anastrozole treatment had no consistent effect on uptake of E1. Endogenous
tumour levels of both E1 and oestradiol (E2) were signiﬁcantly reduced with therapy (P=0.028 for E1 and P=0.0019 for E2).
Anastrozole (1 and 10 mg daily) effectively suppresses aromatase activity, and subsequently oestrogen levels, within the breast
tissue of postmenopausal women with large or locally advanced, operable, oestrogen receptor-rich breast cancers.
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In approximately one-third of cases of advanced breast cancer,
oestrogen deprivation causes tumour regression (Jackson and
Lowery, 1987). This effect is associated with both anti-oestrogens
that block oestrogen receptors (e.g. tamoxifen) and inhibitors of
oestrogen biosynthesis. The latter may be most speciﬁcally achieved
by targeting the aromatase enzyme, which catalyses the ﬁnal step in
the oestrogen biosynthetic pathway (Miller, 1996).
There are two major types of aromatase inhibitors (AIs): Type I
inhibitors are androgens or androgen analogues that block the
substrate binding site on the enzyme; Type II inhibitors are non-
steroidal agents that interfere with the cytochrome P450 moiety
in the aromatase molecule (Miller, 1996). Although the agents
inhibit peripheral aromatase activity, the relationship between
potency in lowering plasma oestrogen levels and clinical effective-
ness in treating breast cancer is poorly deﬁned and it has been
suggested that effects on circulating oestrogens do not entirely
account for anti-tumour inﬂuences (Bajetta et al, 1999). Levels of
oestrogens in the breast tissue (including tumours) of postmeno-
pausal women may be higher than those in the circulation, and
this may result from both increased local synthesis and/or active
uptake from the circulation (Miller, 1996). It is therefore of interest
to investigate the effect that AIs have on aromatase activity and
oestrogen levels in breast tissue.
Anastrozole is a potent, orally active, selective, non-steroidal AI
that markedly reduces the levels of circulating oestrogens in post-
menopausal women with breast cancer (Plourde et al, 1995;
Geisler et al, 1996). As a second-line agent for adjuvant therapy
in postmenopausal women with advanced breast cancer, anastro-
zole has been shown to offer signiﬁcant clinical beneﬁts when
compared with the progestin, megestrol acetate (MA) (Buzdar et
al, 1996, 1998). Anastrozole shows signiﬁcant beneﬁt over tamox-
ifen with respect to TTP (Bonneterre et al, 2000; Buzdar et al,
2000) when given as ﬁrst-line treatment of postmenopausal women
with advanced hormone-sensitive breast cancer. Finally, anastrozole
is highly effective in reducing tumour volume in the neoadjuvant
therapy of breast cancer in postmenopausal women (Dixon et al,
2000). Indeed, 16 out of 18 patients in this trial who were origin-
ally registered for a mastectomy at the trial onset, were suitable for
breast conservation following anastrozole treatment. However, the
effect of anastrozole on tumour aromatase has not been reported
to date.
MATERIALS AND METHODS
Patients and treatments
The eligibility criteria for patients participating in this study have
been described previously (Dixon et al, 2000). In brief, subjects
were postmenopausal women with oestrogen-receptor (ER)-rich
breast tumours (520 fmol mol
71 protein). All breast tumours
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www.bjcancer.comwere operable and either larger than 3 cm (T2 [43 cm], T3,
N0–1,M 0), or locally advanced (T4b,N 0–1,M 0).
Twenty-six patients were recruited into a randomized, double-
blind, single-centre study in which they received anastrozole either
1 or 10 mg orally once daily for 12 weeks, to be followed by deﬁ-
nitive surgery. The random scheme and associated sealed envelopes
were produced by computer software that incorporates a standard
procedure for generating random numbers.
Infusion of radiolabelled steroids
Before initiation of anastrozole, each patient was infused with
20 MBq
3H-D4 androstenedione and 1 MBq
14C-oestrone (E1)i n
50 ml of 95% plasma protein solution and 5% ethanol. The infu-
sion was given as an initial 10 ml bolus followed by an 18-h
infusion at 2 ml h
71. Delivery was by a 50 ml syringe attached
to a Teﬂon-coated tubing and transmitted through a 21-gauge
venﬂon into a peripheral vein. The infusion was immediately
followed by an open wedge biopsy to sample the tumour. Periph-
eral blood (40 ml) and residual infusion ﬂuid were also taken for
analysis.
The process was repeated after 12 weeks of anastrozole therapy,
with breast tissue being removed during deﬁnitive surgery at this
time.
Extraction and puriﬁcation of radiolabelled steroids
The method used to extract and purify radiolabelled oestrogens
from tissue samples was essentially that described by other workers
(James et al, 1987; Reed et al, 1989). Tissue (0.4–0.6 g) was ﬁnely
sliced and pulverised in liquid nitrogen using a microdismembrator
(Braun). The resultant powder was vortexed with radioinert E1
(500 mg in alcohol) in distilled water and left at room temperature
for 30 min. The extract was then added to ethanol:acetone (1:1)
and left at room temperature for 30 min before centrifugation. The
supernatant was decanted and the pellet resuspended in ethanol:a-
cetone (1:1) and recentrifuged. The resultant supernatant was
pooled with the ﬁrst sample and evaporated down to the aqueous
residue, to which methanol (70% in water) was added and left
overnight at –208C. The mixture was then centrifuged and the
supernatant evaporated down to the aqueous residue, which was
partitioned between acetate buffer (0.1 M, pH 4.5) and diethy-
lether. Ether extracts were dried, reconstituted in
hexane:chloroform (80:20) and resolved by chromatography on
Lipidex using serial elution with hexane:chloroform (80:20,
50:50, 40:60). Fractions containing E1 (hexane:chloroform
[50:50]) were evaporated to dryness and reconstituted in ethanol
for further puriﬁcation using thin layer chromatography for 1 h
on silica gel plates using cyclohexane:ethyl acetate (55:45). The
E1 fraction was eluted and read at 280 nm on a spectrophotometer
to monitor recovery. The radioactivity in the fraction was then
measured (in disintegrations per min, d.p.m.) using a scintillation
counter. Plasma samples (10 ml) were extracted with diethylether,
reconstituted in 70% methanol and further processed as above.
Each sample was counted for 5650 min, together with vials
containing known levels of
3H and
14C alone and in combination
and representing the range of absolute d.p.m. and ratio of isotopes
encountered in the study. Control vials were also counted comprising
‘blank’areasfromtheplatesandplasma/tumourextractsfrompatients
notreceivingradioisotopes.Additionally,randomsampleswerecross-
checkedonaseparatescintillationcounterdesignedandsetupforlow
counts as in
14C dating. The cross-over of
14C in the
3H channel was
70.4% to 0.1% and no
3H was counted in the
14C channel.
Random samples were also subject to chemical derivative forma-
tion and shown to have consistent speciﬁc radioactivity throughout
the procedure, thus conﬁrming purity of oestrone fractions (Miller
and Forrest, 1976).
Tumour uptake of E1 was calculated as the ratio of the level of
14C-E1 in the tumour to that in the plasma following its infusion.
Aromatase activity was measured by the synthesis of
3H-E1 from
the infused precursor
3H-D4 androstenedione. Plasma
3H-E1 synth-
esis therefore represents peripheral aromatase activity. However,
tumour aromatase activity cannot simply be taken as tumour
3H-E1 synthesis, since it is likely that some of the
3H-E1 found
in the breast is formed peripherally, secreted into the circulation
and then taken up by breast tissue. A correction factor is derived
from the level of
14C-E1 taken up by the tumour, since any
3H-
E1 present in the breast in excess of that expected from uptake
represents tumour E1 synthesis (Figure 1).
Therefore:
Tumour E1 synthesis 3H-E1 tumourÿ
 3H-E1 plasma614C-E tumour
14C-E1 plasma

Radioimmunoassay of endogenous oestrogens
Tissue samples (approximately 0.4–0.6 g) were extracted as for
radiolabelled oestrogens, apart from the addition of tracer oestro-
gens in place of radioinert steroid. Extracts were then
reconstituted in toluene:methanol (92:8), and subjected to chro-
matography on Sephadex LH-20. Fractions containing either E1
or oestradiol (E2) were then evaporated to dryness and analysed
by radioimmunoassay as described previously (Thijssen et al,
1991; Miller et al, 1998). Level of detection was 40 fmol g
71 for
oestradiol and 62.5 fmol g
71 for oestrone as calculated from the
blanks in the 12 assays performed for sample measurements and
a 99% probability of the value being by chance (Koch and Peters,
1996). Correction for
14C labelled oestrogen in the puriﬁed fraction
for E1 (median 0.32 pmol) ranged from 0.06 to 0.98 pmol and for
E2 0.00 to 0.61 pmol (median 0.18 pmol).
Statistical methods
Differences in peripheral and tumour aromatase activity and
tumour endogenous oestrogen levels between the two treatment
doses (1 and 10 mg) were analysed using analysis of covariance
(ANCOVA), including terms for pre-treatment and treatment
measurements. Differences between assessments (before treatment
and after surgery) were analysed using a paired t-test. Data for
the peripheral and tumour aromatase activity are expressed as
d.p.m.
3H-E1 g
71. Endogenous E2 and E1 levels in breast tumour
are expressed as pmol g
71. Oestrone uptake was expressed as the
ratio of tumour:plasma
14C-E1.
RESULTS
Patient characteristics
Twenty-four out of the 26 patients recruited into the study were
eligible for analysis. Two patients (one in each group) were found
to have ER-negative tumours and so were excluded from the efﬁ-
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Figure 1 Tumour uptake and in situ synthesis of oestrogens as estimated
by measurement of radioactivity.
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drew from the study because of adverse events (headaches,
depression, and tiredness). Thus, the data from 23 patients were
available for analysis. The demographic and baseline tumour char-
acteristics of the remaining patients were comparable between the
two groups (Table 1). The histological tumour volume was a
median 1.9 cm
3 (range 0.1–6.6 cm
3) for the anastrozole 1 mg
group and 1.9 cm
3 (range 0.1–7.5 cm
3) for the anastrozole
10 mg group.
All patients gave their written informed consent, and appropri-
ate ethics committee approval was obtained prior to initiation of
the study.
Peripheral aromatase activity
Before treatment, there was evidence for peripheral aromatase
activity in all 23 evaluable patients (Figure 2). In terms of percen-
tage conversion, these values ranged from 0.39 to 1.91%. Following
12 weeks’ anastrozole treatment (1 and 10 mg) there was a
profound decrease in aromatase activity in all patients, irrespective
of dose. Indeed, in ﬁve cases, no
3H was detected in E1 fractions
from the plasma of treated patients (range of
3H 0–7 d.p.m.,
14C 44–156 d.p.m.). Percentage conversion on treatment ranged
from 0 to 0.18%. The decrease in peripheral aromatase therapy
was highly signiﬁcant (P50.0001) and the median value for inhi-
bition was 94%. There were no signiﬁcant differences between the
two treatment doses (P=0.8793).
Tumour aromatase activity
Before treatment, aromatase activity was detected within the
tumour in 19 of 23 patients and the remaining four tumours
had no evidence for aromatase activity. After 3 months of anastro-
zole therapy, 17 tumours exhibited a fall in activity (Figure 2), two
(from the 1 mg group) showed increased in situ aromatase, and
aromatase activity remained undetectable in four tumours. (The
d.p.m. in the oestrone fractions counted from on-treatment
patients were
3H –1 to 5 (apart from a single tumour with a value
of 13) and
14C 15 to 40.) The difference between pre-treatment and
treated specimens was statistically signiﬁcant (P=0.0009) and the
median value for inhibition was 89% (although it should be noted
that other factors such as the further metabolism of oestrogen may
compromise exact quantitation) (Larionov et al, 2002). There were
no signiﬁcant differences between the two treatment doses
(P=0.34).
Tumour uptake of oestrone
The uptake of E1 into the tumour as measured by the ratio of
14C-
E1 in the tumour to that in plasma is shown in Figure 3. Values
were typically 41 indicating the potential of tumour tissue to
concentrate E1 from the plasma against a concentration gradient.
Whilst treatment with anastrozole could be associated with changes
in uptake, the direction of effect was not consistent, and the differ-
ence between pre-treatment and treatment values was not
statistically signiﬁcant (P=0.53).
Tumour endogenous oestrogen levels
The effects of treatment on tumour levels of E2 and E1 are shown
in Figure 4. In the majority of cases, values fell markedly with ther-
apy (indeed in ﬁve tumours levels of oestradiol were undetectable
after treatment) such that the levels were statistically lower in trea-
ted specimens (P=0.028 for E1 and P=0.0019 for E2). In two
tumours, it was not possible to observe a fall in oestradiol follow-
ing treatment (in one of these tumours oestrone also did not
decrease). There were no signiﬁcant differences between the two
treatment doses (P=0.234).
DISCUSSION
Levels of oestrogens in postmenopausal breast tissue are higher
than those in the circulation, this being at least partly due to local
synthesis (Miller, 1996). Thus, to achieve optimal beneﬁt in post-
menopausal patients with breast cancer it may be necessary for
an AI to block local aromatase activity within breast tumours as
well as peripheral aromatase. Indeed, there is some evidence to
suggest that tumours with aromatase activity are more likely to
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Table 1 Demographic and baseline tumour characteristics of patients
Anastrozole 1 mg day
71Anastrozole 10 mg day
71
Characteristics (n=12) (n=11)
Age (years) 74.1+8.7 69.6+8.8
Weight (kg) 69.6+9.6 75.7+13.4
Height (cm) 156.3+12.2 158.1+12.2
Tumour stage*
T2 11 (91.7) 9 (81.8)
T3 0 (0) 2 (18.2)
T4b 1 (8.3) 0 (0)
Lymph node metastases* 2 (16.7) 1 (9.1)
All values are mean+standard deviation, except: *number (%).
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Figure 2 Effect of neoadjuvant anastrozole on peripheral aromatase ac-
tivity (upper panel) and aromatase activity within the breast (lower panel)
at baseline and after 3 months’ treatment.
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(Miller and O’Neill, 1987; Miller and Dixon, 2001).
The present study has demonstrated that 3 months of neoadju-
vant anastrozole therapy in women with postmenopausal ER-rich
breast cancer markedly suppressed peripheral aromatase activity
in all patients. Similarly, treatment with anastrozole was associated
with a clear decrease in activity in 16 of 19 tumours that demon-
strated in situ aromatase activity pre-treatment. It is worth
considering the reason for the inability to detect a clear reduction
in activity in certain tumours. The fact that, in each of the patients,
peripheral aromatase was profoundly inﬂuenced by treatment
excludes the possibility that either the women were not compliant
to taking the drug or that aromatase activity was in general resis-
tant to anastrozole. The lack of effect would seem therefore either
to be artefactual or speciﬁc to the local environment of the breast.
In these respects, it is worthy of note that a decrease in activity was
lacking in the paired non-malignant breast sample (from the single
patient in whom material was available), whereas the expected
inhibition was seen in all non-malignant samples from patients
whose tumours were also affected (data not shown). This would
seem to exclude the possibility that the tumours differentially
possessed mutant aromatase which was resistant to the inhibitor
(although such phenotypes have been constructed experimentally
(Kadohama et al, 1992). The most likely explanation for the results
is that, at the level of the breast insufﬁcient drug accumulated to
inhibit aromatase activity locally. Whilst this hypothesis is testable
by measuring drug levels within the breast, these were not
performed in the present study. Because aromatase activity is
assessed by measuring
3H oestrone within the tissues, it is possible
that the assessments are compromised by the presence of
3H
oestrone remaining from the initial perfusion performed before
administration of drug. Whilst this cannot be totally excluded
(no tissue was collected immediately before the second perfusion)
no radioactive oestrogen was detected in plasma taken either 14
days after the initial infusion or immediately before the second
infusion; furthermore in a single patient from a separate study
who declined a second perfusion, no radioactivity was detected
in oestrogen fractions derived from breast tissue (data not shown).
Therapy was also associated with a marked reduction in tumour
levels of endogenous oestrogens. Although the study was primarily
set up to measure effects on in situ aromatase within the breast and
not designed to determine quantitative changes in endogenous
oestrogens (which would be complicated by the infusion of
exogenous oestrogen), it was of interest to note that the median
decrease in tumour E2 was 67% and in E1 was 70%. These ﬁgures
are similar to those of another study involving postmenopausal
patients (Geisler et al, 1999) in which 12 weeks of neoadjuvant
therapy with anastrozole 1 mg daily, was associated with a
geometric mean decrease in tumour levels E2 of 89% and E1 of
73%. These two studies demonstrate the potent inhibitory effect
of anastrozole on tumour aromatase resulting in decreased in situ
oestrogen synthesis.
Whilst consistent effects of anastrozole were noted in tumour
aromatase activity and endogenous oestrogens, a more variable
inﬂuence on tumour oestrogen uptake was apparent. Thus, whilst
in general all tumours displayed the ability to concentrate oestrone
from the circulation both before and during treatment, occasion-
ally therapy was associated with marked changes. The possibility
that these reﬂect methodological artefact cannot be completely
excluded since replicate measurements were not possible on
account of the limited size of the sample; however, replicate
samples from other patients not on drug treatment never showed
this degree of variation. It seems likely that the effects are a conse-
quence of the changes in endogenous oestrogens following
treatment with anastrozole and the different direction of effects
reﬂect the differing mechanisms by which tumours may sequester
oestrogen from the circulation.
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Figure 3 Effect of neoadjuvant anastrozole on oestrone uptake, as mea-
sured by the ratio of tumour to plasma oestrone at baseline and after 3
months’ treatment.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(9), 950–955The present study was also able to illustrate the clinical beneﬁt
of inhibiting aromatase activity as monitored by the marked reduc-
tion (450%) in tumour volume (assessed by ultrasound) in 18 of
the 24 patients (Dixon et al, 2000). It should be noted that changes
in tumour aromatase following treatment did not always corre-
spond with clinical behaviour. Thus, two of the three tumours in
which anastrozole did not markedly reduce in situ activity, never-
theless responded to the drug. Presumably, the marked inhibitory
effects on peripheral aromatase were sufﬁcient to reduce tumour
oestrogens and cause tumour response. Similarly, responses in
tumours without aromatase activity are probably a consequence
of inhibitory effects in other peripheral tissues. It is also of impor-
tance that as a result of anastrozole treatment in this study, only
two patients required a total mastectomy. The remaining 16 of
the 18 patients who were originally registered for a mastectomy
only required wide local excision of the tumour.
The endocrinological effects of neoadjuvant anastrozole in the
present report are entirely consistent with its anti-oestrogenic
and anti-proliferative effects on tumour pathology, which have
been reported previously in this group of women (Anderson et
al, 2000), and are also consistent with the clinical efﬁcacy of
the compound in the treatment of advanced breast cancer in
postmenopausal women (Buzdar et al, 1998; Bonneterre et al,
2000; Nabholtz et al, 2000). The results provided no evidence
of any difference in the therapeutic effects of the two doses of
anastrozole (1 and 10 mg) indicating that the currently recom-
mended clinical dose of 1 mg daily is appropriate for
obtaining adequate suppression of oestrogen levels within the
breast.
It is of interest to compare the results of the present analysis
with investigations into the effects of two other newer, potent,
selective non-steroidal AIs (vorozole and letrozole) on breast
tumour aromatase activity. In one study, eight previously untreated
postmenopausal women awaiting mastectomy for breast cancer
were treated with vorozole 2.5 mg daily. After 7 days, median in
vitro tumour aromatase activity was 89% lower than in matched,
control tumour specimens; similarly, median tumour levels of E1
and E2 in treated patients were 64 and 80% lower than in controls,
respectively (de Jong et al, 1997). In another study that employed
identical design and analytical methods to those reported here,
similar levels of decreased tumour aromatase activity and tumour
oestrogen concentrations were found following the use of neoadju-
vant letrozole 2.5 mg daily for 3 months (Miller et al, 1998).
Therefore, anastrozole, vorozole, and letrozole appear to have simi-
lar effects on tumour aromatase activity and tumour oestrogen
levels in women with postmenopausal breast cancer.
In conclusion, anastrozole (1 or 10 mg daily) effectively
suppresses aromatase activity, and thereby oestrogen levels, within
the breast of postmenopausal women with large or locally
advanced, operable, ER-rich breast cancers.
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